Passive immunotherapy of extended peritonitis as abdominal sepsis prevention

Table 1 Indexes of anti-endotoxin immunity in extended peritonitis

	Before treatment, opt.un.	5th day of treatment, opt.un.
High immunity level patients (group I, n = 5)
Anti-LPS-IgA	0.276 ± 0.004 (p₁ > 0.05)	0.452 ± 0.02 (p₂ < 0.001)
Anti-LPS-IgM	0.210 ± 0.03 (p₁ < 0.01)	0.286 ± 0.04 (p₂ < 0.05)
Anti-LPS-IgG	0.121 ± 0.01 (p₁ < 0.01)	0.184 ± 0.02 (p₂ < 0.01)
Low immunity level patients (group II, n = 27)
Anti-LPS-IgA	0.084 ± 0.007 (p₁ < 0.001, p₃ < 0.001)	0.154 ± 0.015 (p₂ < 0.01)
Anti-LPS-IgM	0.202 ± 0.02 (p₁ < 0.05, p₃ > 0.05)	0.213 ± 0.01 (p₂ > 0.05)
Anti-LPS-IgG	0.069 ± 0.008 (p₁ < 0.01, p₃ < 0.001)	0.083 ± 0.007 (p₂ > 0.05)

p₁, evidence between donors and day of admission; p₂, evidence between day of admission and the 5th day; p₃, evidence between patients of different immunity level.

ISSN: 1364-8535